VANCOUVER, Jan. 17 /PRNewswire-FirstCall/ -- AnorMED Inc. (TSX:AOM, AMEX:AOM) announces that Felix J. Baker and Julian C. Baker have filed a report with the U.S. Securities and Exchange Commission disclosing the intention of various entities controlled by them to requisition a special meeting of AnorMED shareholders for the purposes of replacing the Board of Directors with a new slate proposed by them. Felix Baker is a Director of AnorMED Inc. Following the receipt of any such requisition, the Board of Directors of the Company will be meeting to discuss the requisition. AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has a product in Phase III development, a product in Phase II development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases including HIV. Additional information on AnorMED Inc. is available on the Company's website http://www.anormed.com/. Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not expect to update any forward-looking statements as conditions change. Investors are referred to the discussion of the risk factors associated with the Company's business contained in the Company's Final Short Form Prospectus dated December 1, 2005 and filed with Canadian securities regulatory authorities and available on SEDAR. For further information: Dr. Michael Abrams Elisabeth Whiting, M.Sc. President & CEO VP Corporate Development & Communications Tel: 604-530-1057 Tel: 604-532-4667 E-mail: Cell: 604-763-4682 E-mail: DATASOURCE: AnorMED Inc. CONTACT: Dr. Michael Abrams, President & CEO, Tel: (604) 530-1057, E-mail: ; Elisabeth Whiting, M.Sc. VP Corporate Development & Communications, Tel: (604) 532-4667, Cell: (604) 763-4682, E-mail:

Copyright